Recent advances in the contribution of circRNAs to cisplatin chemotherapy resistance in cancers

Worldwide, cancer is a serious threat to the health of citizens of every country, with the incidence and mortality increasing year by year.Cisplatin is the first-line anticancer drug commonly used in clinics and is widely used for the treatment of solid tumors including lung, gastric, liver, bladder, and ovarian cancer.Although cisplatin-based chemotherapy has a high clinical response efficacy, patients will inevitably develop drug resistance after repeated use, leading to severe restrictions of its application.Circular RNAs (circRNAs) are a promising class of non-coding RNAs capable of promoting or suppressing cancer via functioning as miRNAs sponges.Recently, an increasing amount of evidence shows that circRNAs are closely related to the cisplatin resistance of cancers.Therefore, standing at the perspective of the cisplatin chemotherapy resistance, this paper reviews the research progress of circRNAs related to cisplatin resistance of various cancers.